# name
Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation

# metadata.dc.description.abstract[].value
The presence of donor-specific antibodies (DSA), mainly against HLA, increases the risk of allograft rejection. Moreover, antibody-mediated rejection (ABMR) remains an important barrier to optimal long-term outcomes after solid organ transplantation. The development of chimeric autoantibody receptor T lymphocytes has been postulated for targeted therapy of autoimmune diseases. We aimed to develop a targeted therapy for DSA desensitization and ABMR, generating T cells with a chimeric HLA antibody receptor (CHAR) that specifically eliminates DSA-producing B cells. We have genetically engineered an HLA-A2-specific CHAR (A2-CHAR) and transduced it into human T cells. Then, we have performed in vitro experiments such as cytokine measurement, effector cell activation, and cytotoxicity against anti-HLA-A2 antibody-expressing target cells. In addition, we have performed A2-CHAR-Tc cytotoxic assays in an immunodeficient mouse model. A2-CHAR expressing T cells could selectively eliminate HLA-A2 antibody-producing B cells in vitro. The cytotoxic capacity of A2-CHAR expressing T cells mainly depended on Granzyme B release. In the NSG mouse model, A2-CHAR-T cells could identify and eradicate HLA-A2 antibody-producing B cells even when those cells are localized in the bone marrow. This ability is effector:target ratio dependent. CHAR technology generates potent and functional human cytotoxic T cells to target alloreactive HLA class I antibody-producing B cells. Thus, we consider that CHAR technology may be used as a selective desensitization protocol or an ABMR therapy in transplantation.© 2023 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.

# metadata.dc.identifier.issn[].value
Betriu, Sergi; Rovira, Jordi; Arana, Carolt; Garcia-Busquets, Ainhoa; Matilla-Martinez, Marina; Ramirez-Bajo, Maria J; Banon-Maneus, Elisenda; Lazo-Ro (2023). Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation. Hla, 102(4), 449-463. DOI: 10.1111/tan.15156

# metadata.dc.source[].value
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

# metadata.dc.subject[].value
Chimeric hla antibody receptor t cells (char-tc)

# metadata.dc.title[].value
Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation